Search

Your search keyword '"Canakinumab -- Reports -- Forecasts and trends"' showing total 1 results
Start Over Descriptor "Canakinumab -- Reports -- Forecasts and trends" Publisher newsrx llc

Refine your results

1 results on '"Canakinumab -- Reports -- Forecasts and trends"'

1. Programmed Death-Ligand 1 PD-L1 Non-Small Cell Lung Cancer NSCLC Market Insights and Forecasts, 2017-2030 - ResearchAndMarkets.com

Subjects
United States. Food and Drug Administration -- Reports, Merck KGaA -- Forecasts and trends, Bristol-Myers Squibb Co. -- Forecasts and trends, Pfizer Inc. -- Forecasts and trends, Durvalumab -- Reports -- Forecasts and trends, Ipilimumab -- Forecasts and trends -- Reports, Canakinumab -- Reports -- Forecasts and trends, Nivolumab -- Reports -- Forecasts and trends, Avelumab -- Reports -- Forecasts and trends, Small cell lung cancer -- Forecasts and trends -- Reports, Pembrolizumab -- Forecasts and trends -- Reports, Epidemiology -- Reports -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Non-small cell lung cancer -- Reports -- Forecasts and trends, Cemiplimab -- Forecasts and trends -- Reports, Market trend/market analysis, Health
Abstract

2020 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- The 'Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results